智通财经APP获悉，英派药业-B(07630)涨超3%，截至发稿，涨2.64%，报12.43港元，成交额306.36万港元。
消息面上，近日，英派药业-B发布公告，根据董事会对本集团截至2026年6月30日止6个月(相关期间)未经审核综合管理账目的初步评估及董事会目前可得资料，本集团预期于相关期间取得：收入约人民币9470万元至人民币1.16亿元，较截至2025年6月30日止6个月(同期)约人民币2520万元增加约276%至359%；期内亏损约人民币8170万元至人民币9990万元，较同期约人民币1.29亿元减少约37%至22%。
此外，英派药业-B公告称，公司已将IMP2794提名为临床前候选化合物(PCC)，为一款 KAT6A特异性降解PROTAC。IMP2794是英派药业依托其自有的靶向蛋白降解平台发现的首个PCC。IMP2794是一种高效且选择性作用于KAT6A的降解剂，对KAT6B的选择性超过1000倍。值得注意的是，IMP2794在多种啮齿类和非啮齿类动物中展现出极高的口服生物利用度，预示其在人体内可能实现理想的药物暴露。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.